We conducted a phase I trial of allogeneic T cells sensitized in vitro against a pool of pentadecapeptides (15-mer peptides) spanning the sequence of CMVpp65 for adoptive therapy of 17 allogeneic hematopoietic cell transplant recipients with cytomegalovirus (CMV) viremia or clinical infection persisting despite prolonged treatment with antiviral drugs. All but 3 of the patients had received T celledepleted transplants without graft-versus-host disease (GVHD) prophylaxis with immunosuppressive drugs after transplantation. The CMVpp65-specific T cells (CMVpp65CTLs) generated were oligoclonal and specific for only 1 to 3 epitopes, presented by a limited set of HLA class I or II alleles. T cell infusions were well tolerated without toxicity or GVHD. Of 17 patients treated with transplant donor (n ¼ 16) or third-party (n ¼ 1) CMVpp65CTLs, 15 cleared viremia, including 3 of 5 with overt disease. In responding patients, the CMVpp65CTLs infused consistently proliferated and could be detected by T cell receptor V b usage in CMVpp65/HLA tetramer þ populations for period of 120 days to up to 2 years after infusion. Thus, CMVpp65CTLs generated in response to synthetic 15-mer peptides of CMVpp65 are safe and can clear persistent CMV infections in the post-transplantation period.
INTRODUCTION
Cytomegalovirus (CMV) infections remain a major cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HCT) recipients [1, 2] . Although prophylactic or preemptive treatment with ganciclovir or foscarnet has reduced the incidence and mortality of early CMV infections, prolonged antiviral treatment may delay recovery of virusspecific immune responses and predispose patients to lateonset disease [2] [3] [4] [5] . Furthermore, treatment with antiviral drugs often cannot be sustained because of complicating myelosuppression or nephrotoxicity [2] .
Reconstitution of CMV-specific CD8 þ cytotoxic T cells (CMVCTLs) after HCT is correlated with control of CMV infections [2, [6] [7] [8] [9] [10] [11] [12] [13] [14] . Riddell et al. [15, 16] first demonstrated that adoptive transfer of donor-derived CD8 þ CMVCTL clones sensitized with autologous CMV-infected fibroblasts could protect allogeneic marrow recipients from infection. Subsequent studies employing CMV-specific, predominantly CD8 þ ,
T cell lines sensitized with autologous dendritic cells (DCs) or peripheral blood mononuclear cells (PBMCs) loaded with lysates of CMV-infected cells [17, 18] or single peptides of immunodominant antigens, such as CMVpp65 [19] or DCs transduced to express immunogenic CMV proteins [20] , have further documented the potential of such cells to prevent or treat CMV disease. However, regulatory concerns persist regarding the use of infected cell lysates or virus-transduced cells. Similarly, sensitization with single peptides presented by specific HLA alleles, however prevalent, may limit their broad application. We previously reported a method for generating CMVCTL by sensitization with autologous DCs loaded with a pool of 138 synthetic pentadecapeptides (15-mers) with 11 amino acid overlaps spanning the amino acid sequence of CMVpp65 [21] . With this approach, we were able to generate CMVpp65 peptideespecific T cell lines (CMVpp65CTLs) from each CMVseropositive donor tested, regardless of HLA type, and to characterize these lines as to their epitope specificities and HLA restrictions [21] . We now report results of a phase I trial reassessing the safety and antiviral activity of escalating doses of transplant donor-derived CMVpp65CTLs generated by this technique in allogeneic HCT recipients with CMV infections or persistent CMV viremia. By defining the epitope specificity, HLA restriction, and TCR V b usage of the T cells infused, we were also able to sequentially follow their growth and persistence in vivo and correlate their expansion with clearance of infection.
MATERIALS AND METHODS

Design of Clinical Trial
This single-institution phase I trial was designed to assess the toxicity and activity of escalating doses of CMVpp65CTLs derived from T cell lines generated from CMV-seropositive healthy marrow transplant donors by sensitization in vitro with autologous, cytokine-activated monocytes (CAMS) loaded with a pool of synthetic 15-mer peptides spanning the sequence of CMV protein pp65 [21] . The trial was approved by the institutional review/privacy board at Memorial Sloan-Kettering Cancer Center, the National Marrow Donor Program, and the Food and Drug Administration. Eligible patients were allogeneic HCT recipients who either had clinical CMV infection or CMV viremia that was persistent despite at least 2 weeks of treatment with antiviral drugs or those who could not be maintained on antiviral drugs because of associated toxicities.
Four dose levels of transplant donor-derived CMVpp65CTLs were sequentially evaluated: group 1 (n ¼ 3) received 5 Â 10 5 T cells/kg; group 2 (n ¼ 4), 1 Â10 6 T cells/kg Â 1 dose; group 3 (n ¼ 3), 2 Â 10 6 T cells/kg Â 1 dose; group 4 (n ¼ 6), 1 Â 10 6 T cells/kg Â 3 weekly doses. Endpoints included incidence and severity of toxicities and acute graft-versus-host disease (GVHD) as well as the clinical and virological responses observed and their correlation with alterations in CMV-specific T cells detected after infusion.
Patient and Donor Characteristics
Characteristics of the 16 patients who received transplant donorderived CMVpp65CTLs, including diagnoses, disease status at time of transplantation, conditioning regimen, and type of transplantation, are summarized in Table 1 . All recipients were CMV-seropositive before transplantation.
All patients had been previously treated with antiviral drugs, according to standard of care before administration of CMVpp65CTLs. Antiviral therapy was maintained after CMVpp65CTL infusion in 13 patients but had been discontinued in 4 patients (unique patient numbers [UPN] 4, 5, 8, and 11) because of intolerable toxicities at time of CMVpp65CTL infusion. UPN 17 was referred from an outside center with reactivation of drugresistant CMV after a 9/10 HLA-matched (HLA-A mismatch) HCT from a seronegative unrelated donor. This patient was treated with partially matched third-party CMV cytotoxic T cells (CTLs) under an institutional review board and Food and Drug Associationeapproved single patient use-IND.
Generation of Antigen-Presenting Cells
Autologous transplant donor-derived CAMS and Epstein-Barr virusetransformed B lymphocyte cell lines (EBV-BLCLs) were generated as previously described [21] [22] [23] [24] . To identify HLA restrictions of CMVpp65CTL, a panel of EBV-BLCLs of defined HLA types were generated as previously described [21, 22] .
Generation of Clinical Grade CMVpp65CTLs
Cultures of CMVpp65-specific T cells from seropositive transplant donors were initiated at first detection of CMV viremia or before reactivation for seropositive transplant recipients at risk. CD3
þ -enriched T cell fractions, isolated from PBMC by depletion of adherent monocytes and immunoadsorption of natural killer cells, were initially stimulated at an effector to stimulator ratio of 20:1 with irradiated (6000 cGy) autologous CAMS loaded with the pool of overlapping pentadecapeptides of CMVpp65 (Invitrogen, Boston, MA) and propagated in vitro with weekly restimulation at an effector to stimulator ratio of 4:1 and supplementation with IL-2 beginning at day 10 to 16, as previously described [21, 22] . After 28 days, T cells were harvested, counted, and tested for antigen-specific cytotoxicity and lack of alloreactivity [21] [22] [23] as well as for microbiological sterility and endotoxin levels. Aliquots of CMVpp65CTLs meeting release criteria were and/or CD4 þ CMVpp65-specific T cells were quantitated using a modification of the techniques of Waldrop et al. [25] as previously described [21] [22] [23] . Quantitation of tetramer þ T cells was performed using CMVpp65 MHCpeptide tetramers for HLA A*0201, A*2402, and B*0702 bearing peptide sequences NLVPMVATV, QYDPVAALF, RPHERNGFTV, and TPRVTGGGAM respectively (Beckman Coulter, Fullerton, CA) as previously described [22] .
Functional Characterization and Epitope Mapping by Intracellular IFNgamma Assay
Epitope identification was performed using a mapping grid of CMVpp65 peptide subpools as previously described [21] . T cell responses to specific peptides or subpools of CMVpp65 were quantitated by measuring the number of IFN-g þ T cells generated upon secondary stimulation with autologous peptide-loaded antigen-presenting cells [21] [22] [23] .
Cytotoxicity of CMVpp65CTLs In Vitro
CMVpp65CTLs were assessed for their capacity to lyse CMVpp65 loaded targets using a standard 51 chromium release assay [23, 24] . Targets used in all experiments included peptide-loaded and unloaded autologous and fully allogeneic phytohemagglutinin (PHA) blasts. To define the HLA restriction of epitope-specific CMVpp65CTLs, the cytotoxic activity was measured against a panel of EBV-BLCL or PHA blasts loaded with the peptide, each sharing with T cells of a given donor a single HLA allele, as previously described [21, 24] .
Analysis of TCR V b Repertoire within CMVpp65CTL
The CMVpp65 peptide-HLA tetramer þ T cells contained within each CMVpp65CTL line were analyzed for TCR V b repertoire by fluorescent activated cell sorter, as previously described [22] , using a commercially available kit (IO Test Beta Mark, Beckman Coulter, France) according to procedures provided by the manufacturer [26] .
Monitoring of Patients and Follow-up after CMV CTL Infusion
Patients were sequentially monitored for toxicities using the Common Terminology Criteria for Adverse Events (version 4, 2009) and for acute GVHD as graded by the Center for International Blood and Marrow Transplant Research Consensus [27] .
CMV in the blood was measured by quantitation of CMV antigenemia in the initial 8 patients and by CMV polymerase chain reaction thereafter, using methods previously described [28] [29] [30] [31] . CMV levels were monitored before the T cell infusion, at weekly intervals for 6 weeks thereafter and monthly until clearing or clinical progression.
T cell responses were measured by quantitating IFNg þ T cells in response to the total pool of CMVpp65 peptides as previously described [21, 22] . The CMVpp65 epitope specifications and HLA restrictions of the T cells in the blood were identified as discussed above. After infusion of T cells known to contain CMV peptide/HLA tetramer þ T cells, the tetramer þ T cells were also monitored by fluorescent activated cell sorter [21, 22] . In addition, the TCR V b repertoires of the tetramer þ cells or IFNg þ CMVpp65CTLs were characterized both in the CMVpp65CTLs infused and sequentially in the patient.
RESULTS
Patient Status before Infusion of CMVpp65CTLs
Of the 16 patients treated with transplant donorederived CMVpp65CTLs after allogeneic HLA-matched related (n ¼ 12) or unrelated (n ¼ 4) HCT, 2 (UPNs 1 and 2) received unmodified allogeneic HCT with post-transplantation immunosuppressive drugs as GVHD prophylaxis. UPN 1 was on standard doses of cyclosporine A and mycophenolate mofetil at time of treatment. UPN 2 was being treated for active GVHD, grade III, of skin and gut with cyclosporine A 200 mg every 12 hours, mycophenolate mofetil 1 gm every 12 hours, and methylprednisolone .5 mg/kg daily. Patients 3 through16 received T celledepleted HCT without immunosuppressive drugs to prevent GVHD. UPN 13 had been treated with parenteral steroids for grade II acute GVHD of the gut before CTL infusion, but by the time of CTL infusion, the patient was off all immune suppression. As detailed in Table 2 , each patient received extensive treatment with antiviral drugs before adoptive transfer of CMVpp65CTLs and had either not responded or was intolerant to further drug therapy. The median time to CMV reactivation after allogeneic HCT was 36 days (range, 0 to 94 days). The median time to first treatment with CMVpp65CTLs after allogeneic HCT was 120 days (range, 78 to 164 days). All patients had persistent CMV viremia at time of treatment with CMVpp65CTLs. Three patients (UPNs 1, 6, 7) had concurrent interstitial pneumonia but biopsy or bronchoalveolar lavage was refused before treatment. Two patients (UPNs 5 and 9) were diagnosed with CMV retinitis, including 1 with meningoencephalitis (UPN 19).
Characterization of T Cells Infused
CMVpp65CTLs were predominantly CD8 þ in 14 of 15 lines tested (Table 3) . Tetramer þ CMVpp65CTLs were primarily (!97%) of the CD62L À , CCR7
À , CD45RO effector memory phenotype. However, small populations of tetramer
T central memory cells were detected in 6 of 8 lines tested.
Responding T cells were specific for a single pentadecapeptide derived from CMVpp65 in 9 of 15 cases adequately tested ( Table 3 ). The peptide epitopes identified in these 9 lines and their presenting HLA alleles are described in Table 3 . Six lines (UPNs 6, 7, 9, 11, 12, 14) contained (Table 3) .
Clinical Outcomes and Toxicities
Infusions at each dose level were well tolerated. No patient experienced fever, alterations in vital signs, or other toxicities over the course of the first 48 hours of observation. No patient developed manifestations of de novo acute GVHD. Furthermore, neither of the 2 patients who had GVHD (UPNs 2 and 13) before infusion exhibited an exacerbation or worsening of their GVHD.
As summarized in Table 4 , clearance of CMV was observed in 14 of 16 patients. Five patients had presumed or documented CMV disease before adoptive therapy. Two with documented CMV retinitis cleared their disease. Of the 3 patients with interstitial pneumonia, UPN 7 failed to respond over 31 days follow-up and died of pneumonia without clearing CMV. UPN 1 cleared CMV viremia within 14 days of infusion but died of pneumonia 36 days after CTL infusion. Bronchoalveolar lavage obtained in the week before her death was positive for Mycobacterium avium but negative for CMV. UPN 6 exhibited delayed clearance of CMV antigenemia, with persisting interstitial pneumonia. She cleared her CMV viremia by 47 days after infusion but died of persistent pneumonia 12 days later. Bronchoalveolar lavage 7 days earlier was CMV negative.
Of 11 patients who received CMVpp65CTL as treatment for viremia persisting despite antiviral treatment, 10 cleared their viremia. In 1 patient (UPN 13), CMV viremia was not cleared but reduced from 3649 to < 500 copies CMV DNA/mL by 21 days after infusion (day 109 after HCT). This patient subsequently received steroids for pre-existing grade 2 intestinal GVHD. CMV viremia recurred; the patient subsequently died of sepsis 132 days after infusion.
Of the 16 patients, 12 were still maintained on antiviral drugs for periods of 15 to !36 days after T cell infusion. However, for 4 patients (UPNs 4, 5, 8, and 11), antiviral drugs were discontinued within 1 (UPNs 4, 5, and 11) or 3 weeks (UPN 8) of receiving CMVpp65CTL because of intolerable drug induced toxicities. Despite this, all cleared their viremia, including UPN 5, who had advanced retinitis before initiation of T cell infusions.
Alterations of Circulating CMV-specific T Cells after Adoptive T Cell Transfer and Their Correlation with CMV Viremia
Results of sequential quantitation of IFNg þ T cells and/or CMVpp65-HLA tetramers are summarized in Table 5 potentially reflecting coexpansion of T cells specific for the epitope presented by HLA-A*0201 detected in the patient before CMVpp65CTL infusion. The kinetics of expansion of the CMVCTL after infusion and their correlation with alterations in CMV viremia are illustrated by 3 representative patients, UPN2, UPN5, and UPN8 (Figures 1 through 3) . As shown in Figure 1 , of the T cells administered to UPN2, 71% bound HLA-A*0201/NLV tetramers ( Figure 1A ). Infusion of these T cells was initially followed by a peak of CMV antigenemia followed by an abrupt fall to undetectable levels that was contemporaneous with the detection of expanding populations of CMVpp65/ HLA-A*0201 tetramer þ cells in the blood ( Figure 1D ,G,E). The CMVpp65CTLs infused into UPN5 ( Figure 3 ) were also specific for these 2 epitopes presented by HLA-B*0702; 4.2% of the T cells bound HLA B*0702 tetramers bearing the TPR peptide and .2% bearing the RPHER peptide ( Figure 3B ). CMVpp65CTLs were administered after failed treatment with Valcyte (Genentech, San Francisco, CA) and initiation of foscarnet, at maintenance dosing only, because of associated toxicity. Again, reduction of CMV antigenemia was observed only with the emergence of TPR/HLA-B*0702 tetramerbinding CMVCTL and cleared 2 weeks after infusion, at which time foscarnet maintenance was stopped. Thereafter, the patient remained free of CMV antigenemia ( Figure 3A) . Levels of TPR/HLA-B*0702 tetramer þ cells decreased by 16 weeks after infusion but have remained detectable throughout follow-up. In addition, by day 90 after infusion ( Figure 3C ), limited numbers of HLA-A*0201-restricted T cells specific for the NLV peptide were also detectable. At 2 years after infusion ( Figure 3D ) T cells specific for TPR and RPHER are still prominent, as are the NLV specific T cells first detectable at day 90. To further delineate the contribution of the adoptively transferred CMVpp65CTLs to the CMVCTL detected after CMVpp65CTL infusions, we examined the TCRs of isolated MHC-peptide tetramer þ T cells for their V b usage as shown in 1  A24  60  510  80  D  D  D  D  D  IFN  60  280  10  D  D  D  D  D  2  A2  200  900  1800  2200  3900  4200  1400  900  IFN  120  400  500  1400  1100  1800  900  500  3  A2  50  600  170  740  760  2500  2000  1200  B7  120  530  80  430  140  1000  720  400  IFN  0  360  44  30  60  800  2700  800  4  A2  0  50  100  70  0  200  50  100  B7  0  1764  2200  90  533  6100  8400  11800  IFN  0  172  240  100  400  2900  3300 NT  NT  NT  NT  NT  NT  NT  IFN  0  70  40  200  120  192  D  D  11  NT  NT  NT  NT  NT  NT  NT  NT  NT  IFN  0  256  384  480  512  352  160  320  12  NT  NT  NT  NT  NT  NT  NT  NT  NT  IFN  0  2200  830  732  300  400  3050  1100  13  NT  NT  NT  NT  NT  NT  NT  NT  NT  IFN  0  5  3  15  40  80  290  140  14  A2  860  2246  435  2423  8629  5707  2912  NP  IFN  0  270  140  822  2308  1711  1240  NP  15  NT  NT  NT  NT  NT  NNTT  NT  NT  NT  IFN  92  2369  1130  1560  498  325  246  269  16  A2  45 Taken together, these data support the hypothesis that the T cells responding to and clearing CMV viremia early after adoptive transfer are the CMVpp65CTLs infused, whereas CMVCTL detected late after infusion are a mix of the CMVpp65CTLs transfused and other CMVCTL generated from expansion of undetected small populations of CMVCTL in the transferred cells, expansion of T cells from residual mature CMVCTL in the patient's transplantation, or new CMVCTL developing from precursors in the graft that mature in the host thymus.
We similarly assessed the activity of third-party donorderived CMVpp65CTLs in 1 patient. UPN 17 received an unmodified (HLA-A) mismatched unrelated transplant from a CMV-seronegative donor at another center. CMV viremia developed after transplantation but failed to respond to antiviral therapy. The patient's CMV was found to be resistant to foscarnet, ganciclovir, and cidofovir by mutational analyses. As shown in Figure 5 , this patient received 3 weekly doses of 1 Â 10 6 third-party CMVpp65CTLs/kg that were matched for 2 HLA alleles and specific for the NLV peptide presented by the HLA-A*0201 allele shared by patient, transplant donor, and third-party CMVpp65CTL donor. After the first infusion, CMV DNA rose to 800,000 copies/mL blood but then declined after the second dose and subsequently cleared 21 days after the third dose of HLA-A*0201/NLVrestricted third-party CMVpp65CTLs. Figure 5C illustrates the corresponding incremental increase in HLA-A*0201/NLV tetramer þ CMVCTL frequencies in the patient's blood from .7% on day þ14 to 5.6% on day þ150 after infusion. We also documented an increase in the IFN-g þ T cell frequencies responding to the total pool of CMVpp65 peptides and, specifically, the NLV peptide to 1.5% by day þ49.
DISCUSSION
In 2005, our group described a technique for generating CMVpp65CTLs based on sensitization of HCT donor-derived T cells with autologous CAMS loaded with a pool of 138 synthetic 15-mer peptides spanning the sequence of CMVpp65 [21] . We selected CMVpp65 because of the many proteins generated by CMV, CMVpp65 induces T cell responses of the greatest magnitude and in the highest proportion of individuals, the second most immunogenic being the immediate early antigen 1 (IE-1) [32] [33] [34] . More recent studies also indicate that presentation of CMVpp65 peptides, which does not require new protein synthesis, may be less susceptible to inhibition by subsequently generated evasins, the noncoding RNAs generated by CMV that can interfere with antigen processing and transporter associated with antigen processing (TAP)-mediated transport of antigen peptides to HLA alleles for presentation [35, 36] .
In this phase I trial, we tested the activity of transplant donorederived T cells sensitized with the pool of overlapping 15-mer peptides of CMVpp65 in a series of allogeneic HCT recipients who had either clinically overt infection or CMV viremia persisting despite prolonged treatment with antiviral drugs. As shown in Table 2 , only 1 patient had received less than 2 antiviral drugs. All had been treated for periods of 7 to 18 weeks and at time of adoptive transfer had stable or increasing levels of CMV antigenemia or CMV DNA in the blood, despite antiviral therapy. Such patients have been reported to have a markedly increased mortality due to CMV disease and associated infections [37] [38] [39] .
The CMVpp65CTL infusions, at all doses, were well tolerated without clinical toxicities. Furthermore, no patient developed de novo acute or chronic GVHD or a flare of existing GVHD after adoptive transfer. This finding is similar to our own and other reported experiences with adoptive transfer of EBV-specific T cells sensitized with autologous EBV BLCL over 3 to 5 weeks in vitro [40] [41] [42] [43] to deplete allo responsive T cells.
Of the total of 17 patients treated, all but 2 (UPNs 7 and 13) achieved durable clearance of CMV viremia. Of the 3 patients treated who had interstitial pneumonia at time of first infusion, 2 cleared CMV (UPNs 1 and 6) but all 3 ultimately died of complications of interstitial pneumonia, 1 with a concurrent mycobacterium avium intracellulare (MAI) infection (UPN 1). Feuchtinger et al. [44] have also reported continued pulmonary deterioration despite clearance of CMV. These findings raise concerns that treatment with CMVCTL may initially augment inflammatory responses in infected tissues resulting in additional tissue damage. On the other hand, UPN 5 and UPN 9 each had documented CMV retinitis that cleared without residual retinal damage.
Although groups of patients received escalating total doses of CMVpp65CTLs ranging from .05 to 2.0 Â 10 6 /kg, the actual doses of CMVCTL provided at each dose level, as (Table 3) . However, we did not discern a relationship between clinical and/or viremic response and doses of CMVpp65CTLs/kg administered or the absolute doses of CMVCTL provided. On the other hand, clinical response was consistently correlated with expansion of CMVpp65-reactive T cell populations in vivo. These increments in the frequencies of CMVCTL were detected as early as day 7 and usually peaked by day 28. After clearance of CMV, CMVCTL levels fell to steady states that were maintained through 5 to 24 months of observation. In contrast, the 2 patients who failed to clear CMV had no significant increments in the frequencies of circulating CMVCTL. Failure of in vitroeselected CMVpp65CTLs to proliferate after adoptive transfer has also been correlated with treatment failure by other groups [17, 20, 45] , providing evidence both for the need to expand effector T cell populations to achieve viral clearance and the therapeutic potential of even small numbers of effector cells if they replicate sufficiently in vivo [44] . However, the factors contributing to a lack of proliferation are still poorly defined. In recipients of unmodified HCT treated for CMV, ongoing treatment of GVHD with immunosuppressive drugs, particularly glucocorticosteroids, has been implicated [2, 46] . However, in our series, all but 2 patients received T cell depletedetransplants administered without immunosuppressive drug prophylaxis. In trials exploring adoptive T cell therapy for EBV-associated lymphomas complicating allogeneic HCT, failure of T cells to expand in vivo has also been correlated with treatment failure and has been ascribed to the inability of transferred T cells to recognize the EBV þ lymphoma cells either because the EBV epitope targeted by the T cells is deleted or mutated [40, 47] or, in HLA-disparate patients, because the T cells transferred are restricted by an HLA allele not shared by the tumor. Thus far, mutations in immunogenic peptides of CMVpp65 that would affect their recognition by HLArestricted CMVpp65-specific T cells have been found to be infrequent among clinical isolates [48] . However, CMV has developed a multitiered array of microRNAs, termed evasins, that can prevent the recognition or killing of infected cells by T cells. For example, evasins such as US2, 3, 6, and 11 can disrupt the membrane localization and stability of specific MHC class I alleles, thereby impairing their expression [35, 49, 50] . US3 and US6 can also prevent the transport and loading of processed peptides on HLA class I alleles for presentation to T cells [36] . In addition, Kim et al. [51] have recently shown that a CMV micro RNA US4-1 can downregulate the expression of an aminopeptidase essential to the editing of antigenic peptides during their processing within the endoplasmic reticulum. Unfortunately, we did not have infected cells or the viral isolates from the 2 patients who failed to clear CMV to examine whether 1 or more of these mechanisms may have contributed to the apparent failure of the transferred T cells to recognize and expand in response to infected cells in the host. Recently, other groups have also employed CMVpp65 15-mer peptide pools to stimulate the propagation of CMVspecific T cells. Thus, Bao et al. [52] employed overlapping peptides of CMVpp65 and IE-1 to generate transplant donorederived CMV-specific T cells for treatment of CMV viremia persisting despite antiviral treatment for >2 weeks in 7 patients, including 5 who had received T celledepleted haploidentical grafts. Of these, 3 cleared CMV viremia and 3 had significant reduction of viral load, each associated with increments in circulating levels of CMV-specific T cells. More recently, Peggs et al. [53] and Feuchtinger et al. [44] evaluated donor-derived CMV-specific T cells rapidly generated from the blood by sensitization for 16 hours with a pool of overlapping CMVpp65 peptides, followed by immunoselection of interferon geproducing T cells. The median doses of CMVpp65-specific T cells obtained and administered by this approach are low (2 to 10 Â 10 3 /kg), which limits analysis of their specificities. Nevertheless, as shown by Feuchtinger et al. [44] , such T cell doses can induce durable clearance of CMV in 50% to 60% of allogeneic HCT recipients with CMV infection or persistent viremia who have failed to respond to antiviral drugs. Furthermore, Peggs et al. [53] reported that over 90% of patients treated preemptively for CMV viremia with such T cells clear infection after no or only 2 to 3 weeks treatment with a single antiviral drug. In both studies, in vivo expansion of CMVpp65-specific CD4 þ and/or CD8 þ T cells was also correlated with response.
The group at Baylor College of Medicine has explored T cells simultaneously sensitized to antigens from multiple viruses, including CMVpp65 and IE-1 to elicit CMV-specific T cell responses. Initially, they used autologous dendritic cells or EBV BLCLs transduced with an adenoviral vector directing the expression of CMVpp65, and adenovirus proteins [54] and, more recently, PBMC loaded with pools of overlapping 15-mer peptides from 5 viruses (Adenovirus, EBV, CMV, BK, and human herpes virus 6) [55] to sensitize donor T cells. In initial trials, both approaches have shown promise in limiting viremia [55, 56] and clearing CMV infection or drugrefractory viremia [54, 55] as well as concurrent infections due to other targeted viruses [55] . In the trial of T cells sensitized with pooled peptides from 5 viruses, all of the T cell cultures from seropositive donors generated T cells specific for CMVpp65 or IE-1. This approach has the advantage of addressing infections from each of the viruses most often associated with disease in HCT recipients. However, T cells responding to immunogeneic peptides from different viruses in the pool may also recognize epitopes presented by different HLA alleles on the antigen presenting cells. Although such donor-derived T cells would be expected to consistently include donor T cells specific for viral peptides that are restricted by HLA alleles expressed by infected cells from an HLA-matched recipient, they would not be active in an HLA-disparate patient unless the virus-specific T cells are restricted by an HLA allele shared by infected cells of the host. Thus, in HLA disparate hosts, the utility of such cells may be limited unless the HLA restrictions of the T cells specific for each virus are identified.
For our study, we identified both the epitope specificity and HLA restriction of the CMVpp65-specific T cells so as to gain information regarding the relative immunogenicity of the peptides and to be able to track the responding T cells after infusion and correlate their growth in vivo with clinical activity. Despite the fact that the T cells were sensitized with a pool containing a broad array of CMVpp65 epitopes, of 138 15-mers, the CMVpp65CTLs generated over the 4 to 5 week course of in vitro culture consistently responded to only 1 to 3 peptide epitopes presented by 1 or more class I or II HLA alleles expressed by the donor (Table 3, Figure 1B) . Analysis of the TCR V b usage of tetramer þ T cells specific for these epitopes also revealed them to be oligoclonal ( Figure 4 ). The immunodominance of specific epitopes may have shaped the repertoire of CMVpp65CTLs generated in vitro. However, Kern et al. have observed a similar degree of this immunodominance in vivo in the blood of seropositive donors late after primary infection [57] . As expected from prior reports, epitopes presented by HLA B*0702 were dominant in all 4 donors inheriting this allele, including 3 who coinherited HLA A*0201 [58] . Multicenter trials that accrue large and genetically diverse patient populations will be required to determine if this efficacy of CMVpp65CTLs generated against specific immunodominant epitopes, such as those presented by HLA A*0201 or B*0702, differs significantly from that of CMVpp65 CTL specific to epitopes presented by other HLA alleles. However, even now, the preferential expansion of T cells responding to such immunodominant peptides should be considered also relevant to assessments of different approaches to T cell generation for adoptive therapy. For example, we initially expected that the use of a pool of synthetic overlapping peptides of CMVpp65 for in vitro generation of virus-specific T cells would have the advantage of generating T cells against multiple immunogenic epitopes presented by many different HLA alleles, thus providing a broader repertoire of CMVpp65-specific T cells to combat viral infection than that produced by sensitization with single viral peptides [19, 59] or by isolation of CMVpp65-specific T cells directly from the blood with peptide/HLA tetramers or streptamers [60] [61] [62] . However, our data indicate that the repertoire generated is actually more limited than anticipated and support the hypothesis that small numbers of T cells specific for single highly immunogenic immunodominant epitopes may be adequate to achieve control of viremia and resolution of infection.
On the other hand, our data also raise the possibility that CMVpp65CTLs generated against certain less immunogenic epitopes of CMV presented by other alleles may be less effective, a possibility further supported by recent observations of Giest et al. [63] . Because tetramer and streptamerbased isolation of T cells have thus far been limited to T cells specific for the highly immunogenic and immunodominant epitopes presented by no more than 5 prevalent HLA alleles, particularly A*0201 and HLA B*0702, the excellent responses to such T cells may not reflect these potential limitations.
The technique employed for generating CMVpp65-specific T cells in this study has several advantages, particularly the safety of employing synthetic peptides rather than viral products for T cell sensitization and the consistency with which the technique induces large populations of cytotoxic CD8 and/or CD4 T cells of required CMVpp65-specific and depletions of allo responsive T cells from fresh or shipped blood samples from every seropositive donor in our series. However, the 4 to 5 weeks required for in vitro generation of these CMVpp65-specific T cells remains an impediments to timely treatment unless the transplant donorederived T cells are generated before or at the time of initial CMV reactivation in patients at risk. We adapted this approach for the present study, generating CMVpp65-specific T cells from 30 transplant donors but only treating 16 patients with clinical infection or CMV viremia who failed to respond to antiviral drugs. With the specific consent of the donors, the unused T cells lines were banked for potential use in transplantation patients other than for the individual from whom the donor = Figure 4 . Infused CMV CTLs demonstrate an oligoclonal TCR Vb phenotype represented in specific Vb families, which are also detected after infusion. The TCR Vb phenotype of the infused tetramer positive CMV CTLs (top bar graph) was compared to the TCR Vb of the tetramer þ CMV CTLs recovered from the patient's blood after CTL infusion (bottom mirror image bar graph) at early and late time points.
provided an HCT. One of those banked CMVpp65-specific T cells lines was used to clear CMV in UPN 17. Current single center and planned multicenter phase II trials are comparing transplant donorederived versus HLA partially matched, appropriately HLA-restricted third-party donorderived CMVpp65-specific T cells, again in the treatment of patients with clinical disease or viremia persisting disparate extended therapy with antiviral drugs. Initial results from 2 centers are promising and suggest that virus-specific third-party T cells, which are immediately accessible and broadly applicable but have a shorter survival in vivo, may nevertheless induce clearance of infection in a majority of care [45, 64] .
In conclusion, adoptive transfer of transplant donor or third-partyederived CMVpp65CTLs sensitized in vitro with a pool of synthetic 15-mers peptides spanning CMVpp65 is safe, does not cause GVHD, and can clear CMV infections in high-risk patients who have failed prolonged therapy with antiviral drugs. Strikingly, the CMVpp65CTLs generated consistently exhibited specificity for 1 to 3 immunodominant epitopes presented by a limited number of class I or II HLA alleles. In responding patients, transplant donorederived CMVpp65CTLs proliferate and can be detected for periods of 120 days to up to 2 years after infusion, thereby providing sustained resistance to this pathogen.
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